AstraZeneca has halted its planned £200m Cambridge research site expansion, stalling its entire £650m UK investment package.
The project was expected to create 1,000 jobs but now joins a scrapped £450m vaccine facility in Merseyside.
The company recently pledged $50bn US investment by 2030, funding drug plants and labs across several states.
The pause follows Merck’s cancellation of a £1bn London research hub and Eli Lilly’s suspended £279m gateway lab.
Industry leaders warn the UK is losing appeal as drugmakers face high costs and disputes over NHS pricing policies.
Sanofi said Britain is “not a good place” for life sciences without a clear Treasury-backed plan for competitiveness.
AstraZeneca Pauses £200m Cambridge Expansion Amid Wider UK Pharma Setbacks
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
